VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | Epidemiology and disease characteristics of late-onset MS

Studies have shown that the diagnosis of late-onset multiple sclerosis (MS) has been increasing. Melinda Magyari, MD, PhD, University of Copenhagen, Copenhagen, Denmark, explains that there are currently only a few treatments available for late-onset MS due to fewer treatment opportunities available for older age patients and also immunosenescence, which is prevalent in older age. A lack of evidence for patients being treated with disease modifying therapy, means there is a need for treatments which are specific to individuals with a suppressed immune system. Dr Magyari also highlights the importance of improving diagnosis. This interview took place during the European Academy of Neurology 2021 congress.


Melinda Magyari has served on scientific advisory board, as consultant for, received support for congress participation, or speaker honoraria from Biogen, Sanofi, Roche, Novartis, Merck, Abbvie, Alexion, BMS. The Danish MS Registry received research support from Biogen, Genzyme, Roche, Merck, Novartis.